

ASX Announcement

Race appoints Dr Michelle Rashford Chief Medical Officer

- Seasoned medical affairs & clinical development executive with global oncology experience, Dr Michelle Rashford appointed Race Chief Medical Officer (CMO)
- Dr Rashford brings more than 25 years' senior experience in medical affairs and clinical development.
- Responsible for driving Race's clinical program towards commercialisation

9 May 2023 – Race Oncology (ASX: RAC) is pleased to announce the appointment of Dr Michelle Rashford as Chief Medical Officer (CMO), taking over from Interim CMO, Dr Ajay Duggal.

Dr Rashford is an internationally experienced biopharmaceutical executive and former physician, with expertise in the successful development and commercialisation of pharmaceuticals across oncology, virology, and immunology. Her 25+ years of drug development experience spans large pharmaceuticals to smaller biotech companies and includes pre-clinical and clinical development, medical and regulatory affairs, and drug commercialisation.

Dr Rashford will join Race Oncology on 1 July 2023 from the Japanese Pharmaceutical company Kyowa Kirin, where she has been the Head of Global Clinical Sciences. Prior to her role at Kyowa Kirin, Dr Rashford was the Senior Vice President of Clinical Science at Adlai Nortye Biopharma, where she successfully grew the US Clinical Development team and prepared for the company's Phase III trial. She has also held senior roles within global pharmaceutical companies, including five years at Bristol-Myers Squibb and close to 20 years at Roche in a variety of national and global clinical development roles.

Commenting on the new appointment, Race Oncology CEO and Managing Director Damian Clarke-Bruce said, "This is a significant appointment for Race and given that, we have taken the time to ensure we found the right person. Dr Rashford brings with her vast experience in global clinical development & medical affairs, including more than 20 years of experience specifically in the oncology field. She is a highly respected leader and we look forward to maximising her expertise as we progress our clinical program. Dr Rashford will be critical in optimising our trial design, advancing our clinical engagement, and establishing a strong data and publication strategy, while also enhancing our governance and global reputation amongst the international oncology & cardio-oncology community.

Dr Rashford said, "Race Oncology is an exciting company, and I am delighted to be joining its team of exceptional scientists at a pivotal time in the company's progression. I see great global potential for Race's lead asset and I am committed to harnessing these opportunities to positively impact the lives of patients around the world. I look forward to working closely with interim CMO, Dr Ajay Duggal over the coming months for a seamless transition, and I'm confident Dr Duggal and the Adnovate team will continue to

be excellent clinical partners moving forward, just as they have been over the last six months.”

Dr Rashford holds a Bachelor of Medicine & Bachelor of Surgery from the University of Tasmania, Australia.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target cancer.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in multiple clinical trials in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Damian Clarke-Bruce, CEO/MD on behalf
of the Race Board of Directors
damian.clarke-bruce@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au